Israeli-based medical aesthetic equipment and technology company InMode (INMD.US) loses 9% in pre-market after series of class actions from Hagens Berman, Levi Korsinsky and The Gross Law as well as lower than expected revenues expectations. Not only 'higher for longer' central banks policy but also, Israeli-Gaza war and tensions with Iran negatively impact stock valuation. Previously, company informed that expects rebound in demand, as rates will be lowered but as for now is still unclear will Fed change its policy in summer of 2024.
Company will report full Q1 report on 2 May. As for now, Inmode expects full year 2024 revenues between $485 mln -$495 mln, below avg analysts' estimate of $498.8 mln. Also, Q1 guidance came in lower than expected. Inmode expects $80 mln - $80.1 mln vs average estimate of $102.2 mln. What's more, the aesthetics industry remains significantly affected by the macro environment challenges. On the other hand, company has almost 0 debt and still high both gross and net margins. However, it cyclical business has very strong headwinds as we can see in the stock chart.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appInmode (D1)
Shares are traded below SMA50 / SMA200, and today Wall Street session suggests opening at $17, which is historically the lowest level since company listing. The most important, technical resistance zone is now set at $20 and $22 per share.
Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
